Medications – The COVID-19 Long Haul Foundation

Ivermectin for COVID-19: real-time meta analysis of 63 studies

August 14, 2021 | John Murphy | Leave a Comment

Authors: Covid Analysis, Aug 12, 2021, Version 109 — twitter personality response, added Together Trial (V1 Nov 26, 2020) •Meta analysis using the most serious outcome reported shows 73% and 86% improvement for early treatment and prophylaxis (RR 0.27 [0.16-0.44] and 0.14 [0.08-0.25]), with similar results after exclusion based sensitivity analysis, restriction to peer-reviewed studies, restriction to serious outcomes, and restriction to Randomized Controlled Trials.•61% and […]

Fighting post-COVID fatigue: Here’s what doctors suggest

July 29, 2021 | John Murphy | Leave a Comment

Authors: Rajeswari Parasa When TNM spoke to doctors about the post-recovery phase, they say it takes anywhere between four to twelve weeks for a patient to recover from the symptoms of COVID-19. Doctors suggest that people should limit themselves to doing only mild muscle strengthening and breathing exercises. And that anything beyond mild exercises would […]

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

July 28, 2021 | John Murphy | Leave a Comment

Authors: Yujun Tang,† Jiajia Liu,† Dingyi Zhang, Zhenghao Xu, Jinjun Ji,* and Chengping Wen* Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is the pathogen that causes coronavirus disease 2019 (COVID-19). As of 25 May 2020, the outbreak of COVID-19 has caused 347,192 deaths around the world. The current evidence showed that severely ill patients tend to have a high concentration of […]

Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

July 28, 2021 | John Murphy | Leave a Comment

Authors: Mehmet Soy 1, Gökhan Keser 2, Pamir Atagündüz 3, Fehmi Tabak 4, Işık Atagündüz 5, Servet Kayhan COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes only mild symptoms in the majority of the cases, while immunologic complications such as macrophage activation syndrome also known as secondary hemophagocytic lymphohistiocytosis, resulting in cytokine storm syndrome and acute respiratory distress syndrome, may […]

Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment

July 28, 2021 | John Murphy | Leave a Comment

Authors: Philip C Robinson, Duncan Richards, Helen L Tanner, Marc Feldmann The COVID-19 pandemic continues to wreak havoc on global health-care systems and to claim an increasing number of lives. Although some treatments have shown promise, including dexamethasone and remdesivir, problems remain with access to medication and high mortality despite treatment. Patient selection also appears […]

TNF Biologics and COVID-19: What Autoimmune Patients Need to Know

July 28, 2021 | John Murphy | Leave a Comment

Authors: If you’re taking a type of medication known as tumor necrosis factor inhibitors, also called anti-TNF or TNFis, you may be wondering how these drugs could impact your chances of contracting COVID-19, or having more severe complications from it. After all, the common cold or other upper respiratory tract infections can be more common […]

COVID-19 One Year Later

July 23, 2021 | John Murphy | Leave a Comment

Authors: Giuseppe Novelli, Michela Biancolella, Ruty Mehrian-Shai, Vito Luigi Colona, Anderson F. Brito, Nathan D. Grubaugh, Vasilis Vasiliou, Lucio Luzzatto & Juergen K. V. Reichardt COVID-19 has engulfed the world and it will accompany us all for some time to come. Here, we review the current state at the milestone of 1 year into the pandemic, as declared by the WHO (World Health Organization). […]

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

July 22, 2021 | John Murphy | Leave a Comment

Authors: Romina Libster, M.D., Gonzalo Pérez Marc, M.D., Diego Wappner, M.D., Silvina Coviello, M.S., Alejandra Bianchi, Virginia Braem, Ignacio Esteban, M.D., Mauricio T. Caballero, M.D., Cristian Wood, M.D., Mabel Berrueta, M.D., Aníbal Rondan, M.D., Gabriela Lescano, M.D., et al., for the Fundación INFANT–COVID-19 Group* Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, […]

Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation (COVIDAtoZ)

July 21, 2021 | John Murphy | Leave a Comment

Authors: Milind Desai, M. D, Suma Thomas Principal Investigators: The Cleveland Clinic A Clinical Trail to see whether ascorbic acid and zinc gluconate which has limited side effect profile and is readily available over the counter can decrease the duration of symptoms seen in patients with new diagnosis of COVID-2019. A secondary purpose is to […]

Considerations for Certain Concomitant Medications in Patients With COVID-19

July 21, 2021 | John Murphy | Leave a Comment

Authors: NIH Patients with COVID-19 who are receiving concomitant medications (e.g., angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], statins, systemic or inhaled corticosteroids, nonsteroidal anti-inflammatory drugs, acid-suppressive therapy) for underlying medical conditions should not discontinue these medications during acute management of COVID-19 unless discontinuation is otherwise warranted by their clinical condition (AIIa for ACE inhibitors and […]